Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Xbrane Biopharma AB
AB
Active
Org 5567492375
Solnavägen 3 H, 113 63
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2008 · 18 years old
42 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Xbrane Biopharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
298M
223M
149M
74M
0M
2021: 0M
0M
2021
2022: 58M
58M
2022
2023: 239M (+312% vs 2022)
239M
+312%
2023
2024: 199M (-17% vs 2023)
199M
-17%
2024
2025: 152M (-24% vs 2024)
152M
-24%
2025
EBITDA
SEK millions
295M
102M
-91M
-283M
-476M
2021: -182M
-182M
2021
2022: -168M (+8% vs 2021)
-168M
+8%
2022
2023: -324M (-93% vs 2022)
-324M
-93%
2023
2024: -220M (+32% vs 2023)
-220M
+32%
2024
2025: 143M (+165% vs 2024)
143M
+165%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
152 354
198 721
238 729
57 618
0
Staff expenses
—
—
—
—
—
EBITDA
143 244
−220 414
−324 332
−167 870
−182 011
Depreciation & amort.
—
—
—
—
—
EBIT
143 244
−220 414
−324 332
−167 870
−182 011
Net financials
−20 043
−34 888
−67 413
18
−21 547
Profit before tax
127 559
−252 912
−391 745
−167 714
−192 918
Tax
−2 234
−11 589
−0
−0
−0
Net profit
125 325
−264 501
−391 745
−167 714
−192 918
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
674 915
804 461
600 459
658 373
650 764
Equity
563 075
212 759
173 947
430 872
438 769
Long-term debt
58 308
66 371
112 905
0
543
Short-term debt
53 532
525 331
313 608
227 501
211 453
Total debt
111 840
591 702
426 513
227 501
211 996
Financial ratios
5-year trend
EBITDA margin
94,0 %
This company
15,8 %
Market median
This company
Market median
495% above market
2021
2025
Equity ratio
83,4 %
This company
38,2 %
Market median
This company
Market median
118% above market
2021
2025
Return on equity
22,3 %
This company
18,4 %
Market median
This company
Market median
21% above market
2021
2025
Net profit margin
82,3 %
This company
8,1 %
Market median
This company
Market median
916% above market
2021
2025
Asset turnover
0,23×
This company
1,12×
Market median
This company
Market median
79% below market
2021
2025
Debt / equity
0,20×
This company
0,62×
Market median
This company
Market median
68% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Xbrane Biopharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
